Researchers at the University of Texas Medical Branch at Galveston have developed an Ebola vaccine, the first to be tested against the Makona strain that emerged early in 2014 and has killed nearly 10,000 people. Peter J. Hotez, fellow in disease and poverty, comments on its advantages and drawbacks compared to another Ebola vaccine being tested in humans.
Read the full article in the April 8, 2015, Houston Chronicle.
Dagobert Brito , Robert Curl
Aug 07 2020 | Public Policy
Richard J. Kilroy Jr.
Aug 05 2020 | Center for the U.S. and Mexico